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ABSTRACT OF DISSERTATION 
 
 
 
 
CONTROLLED RELEASE OF OSTEOTROPIC MOLECULES      
STIMULATES IN VITRO CELLULAR ACTIVITY AND  
IN VIVO LOCAL BONE REGENERATION 
 
 
Bone defects treatment and reconstructive surgery continues to increase at a 
significant rate. Current bone defect treatments are autotransplantation, allograft, 
and xenografts create many problems such as, inflammation, infection and 
chronic pain. Moreover, allografts and xenografts arouse immune rejection. 
These problems have led to development of controlled release system for use as 
alternatives to autografts, allografts and xenografts in bone repair. There have 
been many approaches for sustained drug delivery in local bone regeneration 
using biodegradable polymers and osteotropic biomolecules. This dissertation 
presents new approaches that apply intermittent drug delivery for local bone 
regeneration. In the first, the osteotropic molecules simvastatin (Sim) or 
parathyroid hormone (PTH) were released with intermittent profiles. In the 
second, alternating delivery of Sim and PTH as well as alternating release of the 
antimicrobial agent cecropin B (CB) with Sim or PTH. An association polymer 
system of cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) was 
used for the delivery vehicle. Each device showed discrete peaks in release 
profiles and lasted more than 10 days. Release profiles could be controlled by 
altering surface area exposed to aqueous environment, number of layers, loading, 
and blending ratios. Cells were cultured with sustained or intermittent exposure 
to Sim or PTH at various concentrations, and alternating exposure to CB and Sim 
or PTH and to Sim and PTH at different concentrations. Low dose Sim and PTH 
treatments stimulated higher osteoblastic activity than observed in control 
cultures. Furthermore, intermittent delivery was more effective than sustained 
exposure. In vivo, newly formed bone was found in animals implanted with both 
blank Sim-loaded devices. However, a greater anabolic effect was seen for Sim 
release devices. Further, intermittent release devices stimulated the greatest 
woven bone thickness, total bone area, and lamellar bone area. These results 
suggest that intermittent release devices containing a single molecule, Sim or 
PTH, and alternating release devices containing multiple molecules, CB with Sim 
or PTH, possess promising potential as a treatment for local bone regeneration. 
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INTRODUCTION 
Bone loss is an important heath care problem worldwide and current bone 
defect treatments have been mainly focused on replacing the lost bone with 
allogeneic, xenogeneic or synthetic materials. The use of allogeneic or 
xenogeneic tissue for bone repair involves immune rejection, and disease 
transmission. Although autogenic bone grafts are the most successful, they also 
face on additional surgery, and limitation of mount available. One approach to the 
success of bone regeneration via tissue engineering strategies is the proper 
design of the osteogenic molecule delivery devices. The requirements of devices 
for bone regeneration should include controlled released, biodegradability, 
mechanical integrity, and osteogenesis. 
Controlled release technology has been studied for delivering a variety of 
biomolecules at the proper time, with the proper amount, and to the proper site. 
Most commonly, investigators seek to release one drug at constant 
concentrations for extended periods. However, non zero-order kinetics can be 
more desirable than zero-order kinetics for delivery of biomolecules for local 
bone regeneration.  Two osteotropic biomolecules of interest are simvastatin 
(Sim), which is a widely used cholesterol-lowering drug, and parathyroid 
hormone (PTH), which is well known for its role in calcium homeostasis. At the 
systemic level, injections of Sim stimulate bone formation [1-6]. Intermittent or 
pulsatile administration of PTH also has an anabolic effect [7-12], but sustained 
treatment with PTH has catabolic effect on bone [13-15]. In this study, the 
objective was to mimic the intermittent concentrations resulting from daily 
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injections or oral dosing using controlled release methods. 
An association polymer system based on blends of CAP and PF-127 was 
previously investigated for providing pulsatile release of biomolecules [16].  It 
was this CAP and PF-127 association polymer system that was used to develop 
devices for intermittent release of osteotropic molecules.  Because certain bone 
defects can be contaminated with microorganisms, devices for delivery of 
osteotropic molecules with an antimicrobial peptide was also examined.  This 
dissertation reports characterization of the release systems, in vitro bioactivity, 
and the bioactivity for select devices. 
 
BACKGROUND 
The need to treat bone defects resulting from degenerative diseases, trauma, 
and reconstructive surgery continues to increase at a significant rate. Currently, 
bone graft procedures exceed 500,000 in the US and approximately 2.2 million 
worldwide [17]. Harvesting autogenous tissues needs an additional surgery at the 
donor site that can result in its own complications, such as inflammation, infection, 
and chronic pain.  Also, the total amount of bone that can be harvested is limited 
and creates a supply problem.  Although allograft tissue is treated by freezing, 
freeze-drying, gamma irradiation, electron beam radiation, or ethylene oxide, 
because it is obtained from a donor, a risk of disease transmission from donor to 
recipient exists [18]. Xenografts are an alternative approach to helping patients, 
but they still raise concerns with disease transmission and immune rejection. 
These problems have led to development of drug delivery devices, synthetic 
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materials, and tissue engineered constructs for use as alternatives to autografts 
and allografts in bone repair. 
i. Bone Formation    
a.   Intramembranous ossification 
Intramembraneous ossification is the formation of bone on fibrous 
connective tissue and involves making flat bones such as the mandible, skull, 
and some irregular bones. The bone is formed from mesenchymal cells and is 
first formed as connective tissue membranes. Osteoblasts proliferate and migrate 
to the membranes and then differentiate and deposit bone matrix. They finally 
turn into osteocytes and form Woven bone then produce osteons [19,20].  
b.   Endochondral Ossification  
Endochondral ossification happens in long bone formation such as the 
femur and humerus. In this process, bone is firstly formed as hyaline cartilage. 
The perichondrium which surrounds the hyaline cartilage is infiltrated with artery 
and osteoblasts and changes into a periosteum. The osteoblasts form a collar of 
compact bone around the diaphysis. Then, the cartilage in the center of the 
diaphysis begins to disintegrate. Osteoblasts penetrate the disintegrating 
cartilage and replace it with trabecular bone. This forms a primary ossification 
center. Ossification continues from this center toward the ends of the bones. 
After trabecular bone is formed in the diaphysis, osteoclasts break down the 
newly formed bone to open up the medullary cavity. In epiphysis periosteal buds 
recruit mesenchymal cells and blood vessels and the process is similar that in a 
primary ossification center. This is secondary ossification center. Cartilage 
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between the primary and secondary ossification centers is the epiphyseal plate, 
and this epiphyseal plate keeps on forming new cartilage. New cartilage, then, is 
replaced by trabecular bone, and this process contribute to increase length of the 
bone [19,20].  
ii. Controlled Release 
The original goal and direction of controlled release technology is to 
maintain appropriate concentrations of a single drug for extended periods. 
Current drug delivery devices primarily utilize a variety of polymeric biomaterials, 
such as polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) 
(PLGA), polyanhydrides, and polyorthoesters.  Mainly, micro- or nanospheres 
and porous scaffolds have been developed for delivery devices and [21-32]. In 
drug incorporating method, drug can be directly incorporated with delivery 
devices physically or it can be bind by chemically-electrostatic [32], ionic bond 
[33], or covalent bond [34] to devices. 
Many approaches to intermittent biomolecules delivery have been 
investigated, such as injections, oral dosing, pulmonary inhalation and, 
transdermal delivery, [35-41]. In injections, patients may suffer from acute pain, 
and compliance can be problematic for prolonged administration. Oral doing is 
inefficient, because certain many parts of taken drugs can be destroyed in the 
gastrointestinal tract before they reach plasma or they may be excreted. 
Pulmonary inhalation requires continuous inhalation. As a result, a programmable 
device that does not need additional actions is required.   
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iii. Drug release Kinetics 
In most drug release, the rate of drug release changes when the release 
continues. Initially the rate of release relatively large, while at very long times the 
rate of release reaches to zero. In order to characterize the kinetic behavior of 
drug release, it is required to determine how the rate of release varies as the 
reaction progresses [42,43]. 
Rate law is differential equation because the rate of a drug release 
depends on the rate of change of the drug release with time. The differential rate 
law relates to the rate of drug release from the device to the system. Usually, 
differential rate laws have many different forms, however, most drug release 
kinetics belong to one of three differential rate laws [42,43].  
a.   Zero-Order Release  
For a zero-order release, the rate of drug release is a constant. When the 
drug is completely consumed, the release abruptly stops.  
Differential Rate Law:       r = k       Eq. 1 
where k is rate constant, (L mole-1 sec-1). 
       b.   First-Order Release  
For a first-order release, the rate of drug release is directly proportional to 
the concentration of the drug ([A]). When the drug is consumed during the 
release, the concentration and the rate of reaction reduces in the system.  
Differential Rate Law:       r = k a       Eq. 2 
where k is rate constant, (L mole-1 sec-1). 
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c.   Second-Order Release  
For a second-order release, the rate of drug release is directly 
proportional to the square of the concentration of the drug ([A]). For this type of 
release, the rate of release decreases rapidly (faster than linearly) as the 
concentration of the drug decreases.  
Differential Rate Law:       r = k [A]2      Eq. 3 
where k is rate constant, (L mole-1 sec-1). 
iv. CAP and PF-127 Polymer System 
Cellulose acetate phthalate (CAP) is a cellulose derivative that has been 
used in the pharmaceutical industry for enteric coating of oral tablets and 
capsules. While the regulatory status is clear for oral applications (i.e., in FDA 
Inactive Ingredients Guide), it remains unknown with respect to parenteral 
devices. However, Heller’s group has previously used CAP in formulations for 
treating heroin addiction [44,45]. Pluronic F-127 (PF-127) is a triblock copolymer 
of polyethylene oxide and polypropylene oxide. The numerous ether sites within 
PF-127 allow for hydrogen bonding with carboxylic acid groups in CAP. Blends of 
CAP and PF-127 form an association polymer that undergoes surface erosion 
following deprotonation at physiological pH and consequently shows zero-order 
release. In contrast to the commonly used biodegradable polyesters, such as 
poly(lactide-co-glycolide), which undergo bulk hydrolysis, the CAP/PF-127 
system degrades by surface erosion, in which the material degrades from the 
outermost surface toward the inside [16]. The CAP/PF-127 polymer system can 
be used for programmed drug delivery, with the rate, duration, and amount of 
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released drug controlled by blending ratio, number of layers, and thickness 
[16,46,47] 
v. Osteotropic Molecules 
a.   Simvastatin 
Sim is a well-known member of the statin family. Statins are potent pro-
drugs of hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors 
that block conversion of HMG-CoA to mevalonic acid, which is needed for 
cholesterol biosynthesis [48]. Sim inhibits mevalonate, farnesyl pyrophosphate, 
and geranylgeranyl pyrophosphate pathways [49], which are responsible for 
increasing bone mineral density by reducing osteoclastic activity [50]. Statins 
induce expression of bone morphogenetic protein 2 (BMP-2) in vitro, and they 
stimulate bone formation on the calvaria of mice following daily subcutaneous 
injections [1]. Oral dosing with Sim increases cancellous bone volume in rats [51], 
and it also increases transverse area of fracture callus as well as mechanical 
properties compared to controls [2]. Statins offer additional benefits, such as 
promotion of new blood vessel growth [52] and anti-inflammatory effects [53].  
Some literature show skeptical result of Sim on bone formation [54,55]. 
They investigated oral dosing and systemic effect of Sim. However, many studies 
which carried local delivery of simvastatin showed positive effects on bone 
formation not only in vitro but also in vivo. The main difference between systemic 
and local delivery of simvastatin is effective concentration on the wound site. 
Former is absorbed by gastro-intestine system and mainly works in the liver and 
the latter works directly on the wound site. With 60 mg dosage forms, serum 
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concentrations of Sim and simvastatin acid are 18.7 +/- 4.7 ng/ml and 3.5+/-0.5 
ng/ml, respectively. Further, the half-life of simvastatin acid is 5.9 +/- 0.3 hr [56]. 
In local delivery of Sim, we can keep the Sim concentration as high as we can. 
From the result of our study about in vitro simvastatin release [46], we can keep 
the local Sim concentration around 100 ng/ml-210ng/ml.     
Sim has a very low aqueous solubility, approximately 1.4 µg/mL [57], 
because it has a rigid and hydrophobic section that is covalently linked to the 
HMG-like moiety. It has an inactive lactone ring in HMG-like portion. In vivo, this 
inactive lactone ring is enzymatically hydrolyzed to its active hydroxyacid form 
[58]. To increase local concentration of Sim, it is hydrolyzed to cleave the lactone 
ring and convert the molecule to its β-hydroxyacid form [59].  
b.   Parathyroid Hormone 
PTH 1-34 fragment is well known for its role in calcium homeostasis, and 
PTH (1–34) delivery has either an anabolic or catabolic effect on bone, 
depending on mode of delivery. It has been reported that daily injections of low 
doses of PTH (1–34) stimulate bone formation and increase bone mass in 
humans and animals [7,12,14,60-63], whereas continuous administration of PTH 
(1–34) has a catabolic effect  [8,9,15,64]. Many in vivo and in vitro studies have 
been conducted to explain the anabolic effect of PTH (1–34) on bone formation, 
and it is clear that PTH (1–34) enhances proliferation of primary osteoblastic cells 
from humans and animals in vitro [65,66]. In addition, PTH (1–34) exerts diverse 
effects on osteoblast differentiation depending on differentiation stage [67,68], 
and as a result, PTH (1–34) stimulates alkaline phosphatase (AP) activity in the 
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mouse osteoblastic cell line MC3T3-E1 [68].  
      Intermittent administration of PTH shows anabolic effect on bone 
formation by increasing number of osteoblasts [69-72], but the entire cellular 
mechanisms involving this effect are still not fully understand. Many literatures 
have shown that PTH activates survival signaling on osteoblasts and that result 
delays of osteoblastic apoptosis. This is a main way to increasing osteoblast 
number. PTH stimulates multiple intracellular signal pathways, mediated by cAMP, 
and activates both protein kinase A (PKA) and C (PKC) [73]. PTH activates β-
arrestin and β-arrestin activates extracellular regulated kinase (ERK) signaling 
[74,75]. β-arrestin is involved in desensitization of cAMP signaling by PTHr.   
There are significantly fewer PTH receptors on osteoclast cells compared 
to osteoblast cells. Consequently, osteoclast cells are indirectly affected by PTH 
[76]. PTH binds to osteoblast cells and stimulates expression of receptor 
activator of nuclear factor kappa B ligand (RANKL). RANKL binds to osteoclast 
precursors with receptor activator of nuclear factor kappa B (RANK), and 
stimulates these precursors fusing and forming new osteoclasts cells [77]. 
The plasma half life of intact PTH (1–34) is less than 11 min [36]. The fast 
metabolic degradation of PTH requires multiple administrations of PTH to keep 
the effective concentration in the plasma [78]. For example, plasma levels of PTH 
in rats treated by pulmonary inhalation were elevated for less than 120 min 
[36,79].  However, local application of relatively small amount of biomolecules 
will have different requirements.  
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vi. Antimicrobial Agents 
Regeneration of bone defects is complex and involves many sequential 
cascades of events [80]. Furthermore, they may be faced with the threat of 
microbial infection. Once an infection is established, it is difficult to solve the 
problem. Treatment of deep infections requires multiple surgeries, prolonged 
antibiotic treatment, and long-term problems [81]. Therefore, every effort is 
required to prevent this problem with early treatment.  
Continuous use of antibiotics results in increasing resistance to 
antimicrobial drugs, including the occurrence of bacterial strains which are 
resistant to antibacterial agents and has created a public health problem of 
potentially crisis proportions (58). Antibiotic resistance is an evolution via natural 
selection. The antibiotic action is a kind of environmental pressure and  those 
bacteria have a mutation allowing them to survive and reproduce, resulting in a 
fully resistant generation [82,83] 
Cecropin B (CB) is a naturally occurring cationic amphipathic insect 
peptide [84,85] that can notably act not only against certain gram-positive 
bacteria but also against gram-negative bacteria, fungi, and parasites [86-88]. 
The mechanism of action of cecropin B involves channel formation in 
membranes and subsequent lysis [89]. CB has a broad spectrum of EC50 (half 
maximal effective concentration; the concentration of a drug which responses 
half from the baseline to maximum) from 1µM to 20µM, depending on 
microorganism and fungi [86,90,91].  
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vii. Delivery of Multiple Molecules 
Because multiple cascades are required to direct the processes involved 
in bone repair to completion, the success of most current research focusing on 
delivery of a single biomolecule may be limited [92]. A method to overcome 
limitation of single molecule delivery is to release multiple molecules with distinct 
kinetics to trigger the tissue regeneration at the proper site of action [92,93]. 
One of the polymeric multiple biomolecules delivery systems is the use of 
scaffolds and drug loading methods into the scaffolds is that one molecule is 
mixed in scaffold and another drug was encapsulated into microspheres. In this 
method Mooney’s group investigated dual growth factors delivery using PLGA 
scaffold for 40 days. Another approach was made by Mikos’ group, they 
encapsulated dual growth factors and crosslinked them each other [94]. They 
seek for the target of traditional controlled release system-simultaneous 
sustained release system, whereas our devices aimed at short term intermittent 
delivery.  
viii. Significance and Objectives 
Sim has an anabolic effect on bone formation, especially when 
intermittently administered. Similarly, intermittent/pulsatile delivery of PTH can 
promote bone formation, whereas it is destructive is constantly administered.  
There are few studies about local delivery of Sim or PTH with biodegradable 
polymeric devices. Furthermore, there has been no study related to devices 
combining release of Sim and PTH or such devices combined with an 
antimicrobial agent, such as CB.  Developing devices for intermittent delivery of 
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single or multiple osteotropic and antimicrobial molecules for placement in bone 
defects may lead to better treatments for local bone regeneration.   
The objectives of these studies were to develop devices that intermittently 
or sustained release of single molecule (Sim or PTH) and multiple releases of 
molecules (CB/Sim, CB/PTH, or Sim/PTH). The hypotheses were that the mode 
of local Sim release affects in vitro osteoblastic activity and in vivo bone 
formation and that the mode of local PTH(1-34) release affects osteoblastic 
activity. To test these hypotheses, devices for intermittent delivery of Sim or 
PTH(1-34) were developed, and they were demonstrated that the cellular effects 
of Sim or PTH(1-34) on osteoblastic proliferation and differentiation were 
dependent on mode of administration and degree of new bone formation relied 
on mode of release of Sim. 
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Chapter One  
 
BIOERODIBLE DEVICE FOR INTERMITTENT RELEASE OF  
SIMVASTATIN ACID 
 
1.1   INTRODUCTION 
The need to treat bone defects resulting from degenerative diseases, 
trauma, and reconstructive surgery continues to increase at a significant rate.  
More than 500,000 bone grafting procedures are performed annually in the 
United States [95]. Harvesting autogenous tissues requires an additional surgery 
at the donor site that can result in its own complications, such as inflammation, 
infection, and chronic pain. Also, the total amount of bone that can be harvested 
is limited and creates a supply problem. Although allograft tissue is treated by 
freezing, freeze-drying, gamma irradiation, electron beam radiation, or ethylene 
oxide, because it is obtained from a donor, a risk of disease transmission from 
donor to recipient exists [18]. These problems have led to development of drug 
delivery devices, synthetic materials, and tissue engineered constructs for use as 
alternatives to autografts and allografts in bone repair.   
Simvastatin is a well-known member of the statin family. Statins are potent 
pro-drugs of hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase 
inhibitors that block conversion of HMG-CoA to mevalonic acid, which is needed 
for cholesterol biosynthesis [48]. Simvastatin occupies a portion of the binding 
site for HMG-CoA, thus blocking access of substrate to the active site [96]. 
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Mevalonic acid is a precursor not only of cholesterol but also of isoprenoids, such 
as geranyl pyrophosphate, which is important in the control of osteoclast-
mediated bone resorption [97]. Statins offer additional benefits, such as 
promotion of new blood vessel growth (Kureishi et al., 2000) and anti-
inflammatory effects [53]. Most relevant to the present work, Mundy’s group 
originally demonstrated that statins induce expression of bone morphogenetic 
protein 2 (BMP-2) and that they stimulate bone formation on the calvaria of mice 
following daily subcutaneous injections [1]. Subsequent studies have shown that 
oral dosing with simvastatin increases cancellous bone volume in rats [51], and it 
also increases transverse area of fracture callus as well as mechanical properties 
compared to controls [2]. 
For local delivery of simvastatin, typical controlled release devices that 
attempt to achieve zero-order kinetics may not be the most effective. To mimic 
alternating concentrations resulting from daily injection or oral dosing, devices 
providing intermittent release profiles would be useful. We previously 
investigated an association polymer system based on blends of cellulose acetate 
phthalate (CAP) and Pluronic F127 (PF-127) for providing pulsatile release of 
macromolecules [16].   
The objectives of this study were to develop devices that intermittently 
release simvastatin acid and demonstrate that exposure of osteoblastic cells to 
alternating concentrations of the drug enhances bioactivity. 
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1.2   MATERIALS AND METHODS 
1.2.1   Hydrolysis of Simvastatin 
To decrease hydrophobicity of simvastatin (Aldrich, Milwaukee, WI), 42 
mg were dissolved in 1 ml of 95% ethanol, and 1.5 ml of 0.1 M NaOH was added. 
The solution was heated at 50°C for 2 hours.  Then the final solution was 
neutralized to pH 7.2 with 0.1 M HCl, and the volume was brought to 10 ml with 
deionized water [59]. Simvastatin acid (10 mM) was stored frozen at -20°C.   
1.2.2   CAP/PF-127 Microspheres  
Microspheres containing different weight fractions of CAP (Fluka, Buchs, 
Switzerland) and PF-127 (Sigma, St Louis, MO) were prepared by a water-
acetone-oil-water (W/A/O/W) triple emulsion process. Two g of different polymer 
blends of CAP and PF-127 (7:3, 6:4 and 5:5 by weight of CAP:PF-127) were 
dissolved in acetone. One ml of phosphate-buffered saline (PBS), pH 7.4, with or 
without 100 μM simvastatin acid was added to the acetone solution and mixed 
into rapidly stirring corn oil and sonicated. The CAP/PF-127 suspension and 5% 
Triton X-100 were added to deionized water and then stirred to harden the 
microspheres for 5 minutes. Following collection, microspheres were washed 
three times with deionized water, filtered, and dried in vacuum up to seven days.     
Release devices were made using a pressure-sintering process. 
Microspheres were first treated by UV radiation in a laminar flow hood for 30 
minutes. Ten to 15 mg of UV-treated microspheres containing simvastatin acid 
were placed in the wells of a Delrin mold (diameter, 6.2 mm; depth, 20 mm) and 
consolidated by applying 20 MPa pressure for 5 sec. Next, blank microspheres 
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were added on top of the first layer, and pressure was reapplied. By repeating 
this process, six-, eight-, and ten-layer devices were prepared.  To provide 
directional control of drug release, the bottom and sides of the devices were 
coated three times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa; 
Alkermes, Cincinnati, OH) solution in methylene chloride.  
1.2.3.   In Vitro Release 
Samples were immersed in 5 ml of 150 mM PBS, pH 7.4, and incubated at 
37ºC under either static or dynamic (shaking at 80 rpm) conditions using a MaxQ 
Mini 4450 shaker (Barnstead/Lab-Line, Dubuque, IA).  Supernatant was 
collected and replaced daily to maintain a constant volume. To allow 
quantification of released simvastatin acid, CAP was precipitated from the 1 ml of 
supernatant samples by treatment with 0.1 ml of 0.1 M hydrochloric acid. Acid-
treated supernatants were then centrifuged at 1000 rpm for 5 minutes. Solutions 
were placed into 96-well assay plates, along with simvastatin acid standards 
made by serial diluting from a 1 mM stock solution. The concentration of 
simvastatin acid was determined fluorometrically using a SpectraMAX Gemini 
XS ( λex=390 nm, λem=413 nm).   
Profiles were predicted using the approach of [47], who proposed the use 
of nonuniform initial concentration distributions as a means to regulate the 
release of biomolecules from drug delivery devices.  For erosion-controlled 
systems, Eq. 1 describes the fractional release from a planar sheet with initial 
biomolecule distribution f(x), half-thickness a, and erosion rate constant B.   
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1.2.4   Cell Culture  
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manasas, VA) were 
seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α-
Minimum Essential Medium (MEM) containing 10% fetal bovine serum 
(GIBCO/Invitrogen, Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ß-
glycerophosphate (Sigma), and 0-1 µM simvastatin acid.  In a deviation from 
previous simvastatin treatment studies in the literature, medium was exchanged 
every day.  In sustained release cultures, cells were constantly exposed to 
simvastatin acid at a fixed concentration, i.e., the medium always contained the 
same concentration of drug.  In intermittent release cultures, cells were exposed 
to alternating concentrations, i.e., the medium varied between simvastatin-
containing and drug-free medium.  Multiple dilutions of simvastatin acid were 
selected based on preliminary cytoxicity studies.  Medium in control cultures 
was changed on the same schedule, but it did not contain simvastatin acid at any 
time.   
 1.2.5   Assays 
After 3, 7, 10, and 14 days of culture, cells were rinsed twice with PBS and 
then lysed by sonication in a high salt solution (0.05M NaH2PO4, 2M NaCl, and 
2mM EDTA). DNA standards were prepared by serial diluting calf thymus DNA in 
the high salt solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was 
added to DNA standards and samples and allowed to react in the dark for 10 
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minutes [16,98].  The amount of DNA in the samples was determined by 
measuring fluorescence (λex=356 nm, λem=458 nm).   
To measure alkaline phosphatase (AP) activity, cell lysate was incubated 
with substrate solution prepared by dissolving 10 mM of p-nitrophenyl phosphate 
(Sigma) in 0.6 M 2-amino-2-methyl-1-propanol buffer, pH 10 [16]. After 30 
minutes, 0.25 N NaOH was added to each well to immediately stop enzyme 
activity. Absorbance at 410 nm was measured with an MR5000 microplate reader 
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was 
determined using ε=1.7x104 M-1cm-1. Activity was expressed as nmol of substrate 
cleaved per minute and then normalized by DNA content.  
For measuring osteocalcin (OCN) secretion, conditioned medium was 
assayed using an EIA kit (Biomedical Technologies, Stoughton, MA) following the 
manufacturer’s protocol.  Concentrations were determined from a standard 
curve constructed using mouse OCN.   
1.2.6   Statistical Analysis 
Results (mean and standard deviation) were calculated from at least six 
replicate samples. One-way analysis of variance (ANOVA) was conducted using 
the computer application InStat (Graphpad Software, San Diego, CA). Post-hoc 
comparisons were made using the Tukey-Kramer test when the p-value was 
significant (p<0.05).   
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1.3   RESULTS  
1.3.1   Release Profiles 
To create intermittent release profiles, drug-loaded microspheres were 
alternately layered with blank (unloaded) microspheres.  Microspheres were 50-
150 µm in diameter and had a loading of 68-73 ng simvastatin acid per mg of 
polymer.  By multilayering blank and loaded microspheres, six-, eight-, and ten-
layer devices had approximate totals of 3, 4, and 5 µg simvastatin acid, 
respectively.  Figure 1.1 shows both the designed/predicted and experimentally 
determined release profiles for 10-layer devices.  In general, the shape and 
duration of the experimental profile were comparable to those of the 
desired/predicted release profile.  Two differences were noted, however.  
Whereas the designed profile had zero release between the peaks, small 
amounts of simvastatin acid were measured.  In addition, the peak release 
values were not identical to those predicted in the model.  Regardless, the 
desired intermittent release profiles were obtained.  
 Figure 1.2 shows cumulative release of simvastatin acid for the three 
different blend ratios under dynamic release conditions.  All three profiles were 
linear.  The polymer with the highest ratio of CAP to PF-127 (7:3) had a slightly, 
but significantly (p<0.05), slower release rate.  This blend also lasted for a 
longer time, approximately two days longer.  Behavior of the 5:5 and 6:4 blends 
was statistically similar.  And although differences were observed in the rate and 
duration of release, statistically similar total amounts of simvastatin acid were 
delivered for all blends.  
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Figure  1.1.   Comparison between the desired/predicted and the 
experimental release profiles for 10-layer devices (7:3 CAP:PF-127). 
 
Figure 1.3 shows the effect of CAP to PF-127 blend ratio on intermittent 
release of simvastatin acid under dynamic conditions.  All three devices showed 
exactly five discrete peaks, with each layer degrading over two to three days.  
As expected from Figure 1.2, 7:3 blends lasted slightly longer than did 5:5 and 
6:4 devices.   
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Figure  1.2.   Effect of blend ratio on cumulative release of simvastatin 
acid.  Data are the mean of at least six replicates.  Error bars, which 
ranged from 3-11% of the mean, are not shown to prevent obscuring the 
curves.   
 
    The number of layers can be altered to modulate release (Figure 1.4).  Six 
layer devices had exactly three discrete peaks, eight layer devices had four 
peaks, and ten layer devices had five peaks under dynamic release conditions. In 
these experiments, each layer lasted approximately two days, independent of the 
number of layers. 
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Figure  1.3.   Effect of blend ratio on intermittent release of 
simvastatin acid from 10-layer devices.  Data are the mean of at least six 
replicates. Error bars, which ranged from 5-9% of the mean, are not shown 
to prevent obscuring the curves.  
 
The release conditions were also found to affect the kinetics of polymer 
erosion and subsequent release of simvastatin acid (Figure 1.5).  Five discrete 
peaks were seen when samples were degraded under both static and dynamic 
conditions.  Under static release conditions, however, 10-layer devices lasted for 
more than 20 days, compared to only 12 days under dynamic conditions.   
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Figure  1.4.   Effect of number of layers on intermittent release of 
simvastatin acid (blend ratio, 7:3).  Data are the mean of at least six 
replicates. Error bars, which ranged from 3-14% of the mean, are not shown 
to prevent obscuring the curves.   
 
1.3.2   Cytotoxicity 
Degradation products from polymer erosion experiments (i.e., dissolved 
CAP and PF-127 in the PBS) were diluted in cell culture medium and added to 
MC3T3-E1 osteoblastic cells (Figure 1.6).  The undiluted release supernatant 
was considered 100%, and increasing dilutions into the cell culture medium were 
tested.  High concentrations of CAP/PF-127 had a cytotoxic effect, causing cell 
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death.  Even 40% degradation products had a time-dependent, adverse effect 
on the cells (p<0.01).  While cell responses were similar within the first two days 
of exposure, cytotoxic effects became apparent by four days.  At 20% and below, 
however, the cells were unaffected; both the DNA content (reflecting number of 
cells) and production of alkaline phosphatase (reflecting bioactivity) were 
statistically similar to levels in control cultures. 
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Figure  1.5.   Effect of incubation conditions on intermittent release of 
simvastatin acid from 10-layer devices (blend ratio, 7:3).  
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Figure  1.6.   Effect of CAP/PF-127 (7:3) degradation byproducts on 
osteoblastic cells.   
 
1.3.3   Cell Responses to Alternating or Constant Concentrations of 
Simvastatin Acid  
Having determined acceptable levels of degradation products, effects of 
different profiles of exposure to simvastatin acid were investigated. DNA content 
and alkaline phosphatase (AP) activity in MC3T3-E1 cultures exposed to 
pulsatile/alternating and sustained/constant delivery of simvastatin acid are 
shown in Figure 1.7. In all groups, except 1 µM constant concentration, the 
amount of DNA increased until the seventh day, and the growth rates were 
somewhat diminished afterward. Intermittently exposing cells to 1 µM simvastatin 
acid reduced, but did not eliminate, the adverse effect of this higher 
concentration.  Alternating exposure to lower concentrations of simvastatin acid 
increased DNA contents in the earlier stage of culture (p<0.05). AP was elevated 
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by intermittent exposure to simvastatin acid.  Activity was significantly higher for 
the 100 pM and 10 nM alternating groups at 10 days compared to the other 
treatments (p<0.05).   
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Figure  1.7.   DNA content and alkaline phosphatase activity for 
osteoblasts exposed to constant and alternating simvastatin acid.   
 
Results for OCN secretion by MC3T3-E1 cells exposed to alternating and 
constant delivery of simvastatin acid and the controls are shown in Figure 1. 8. In 
control cultures, OCN levels remained relatively constant at low concentration 
(p<0.05).  At day 1, cells constantly exposed to simvastatin acid showed higher 
concentrations of OCN compared to controls and close to levels in cells exposed 
to alternating simvastatin acid.  At days 2 and 4, cells constantly exposed to 
simvastatin acid showed decreased concentrations that then remained fairly 
constant (p<0.05). For 1 µM constant exposure, levels of secreted OCN were 
dramatically decreased compared to the 100 pM and 10 nM constant 
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concentrations. All cells intermittently exposed to simvastatin acid showed 
increased OCN concentrations in the earlier stage of culture (p<0.05), and levels 
remained high. Concentrations were significantly higher for the 10 nM and 1 µM 
alternating groups after 2 days in comparison with the other groups (p<0.05).  
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Figure  1.8.   Osteocalcin secretion for osteoblasts exposed to constant 
and alternating simvastatin acid. 
 
1.4   DISCUSSION 
Simvastatin has an HMG-like moiety, which is present as an inactive 
lactone.  In vivo, this prodrug is enzymatically hydrolyzed to its active 
hydroxyacid form [58].  Simvastatin also has a rigid, hydrophobic section that is 
covalently linked to the HMG-like portion. Consequently, the drug has a very low 
aqueous solubility, approximately 1.4 µg/ml [57]. More hydrophilic molecules can 
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give a higher local concentration. Therefore, the approach used for enhancing 
simvastatin solubility was hydrolysis to cleave the lactone ring and convert the 
molecule to its β-hydroxyacid form [59]. The hydroxyacid form of simvastatin is 
approximately three orders of magnitude less lipophilic than the lactone form [99].   
Cellulose acetate phthalate (CAP) is a cellulose derivative that has been 
used in the pharmaceutical industry for enteric coating of oral tablets and 
capsules. While the regulatory status is clear for oral applications (i.e., in FDA 
Inactive Ingredients Guide), it remains unknown with respect to parenteral 
devices. However, Heller’s group has previously used CAP in formulations for 
treating heroin addiction [44,45]. 
Pluronic F-127 (PF-127) is a triblock copolymer of polyethylene oxide and 
polypropylene oxide. The numerous ether sites within PF-127 allow for hydrogen 
bonding with carboxylic acid groups in CAP. Blends of CAP and PF-127 form an 
association polymer that undergoes surface erosion following deprotonation at 
physiological pH and consequently shows zero-order release.  
In contrast to the commonly used biodegradable polyesters, such as 
poly(lactide-co-glycolide), which undergo bulk hydrolysis, the CAP/PF-127 
system degrades by surface erosion, in which the material degrades from the 
outermost surface toward the inside [16,47]. Therefore, the overall shape of the 
release profiles was linear. When alternating loaded and unloaded layers, flatter 
regions reflecting erosion of the blank layers were also observed.  
As a non-ionic surfactant, PF-127 is readily soluble in water, but CAP is 
swelled and then relatively slowly dissolved in neutral solutions. Consequently, 
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blends containing higher ratios of PF-127 had shorter duration delivery profiles.  
But the overall effect was small, in contrast to the work of Lee, in which larger 
differences in erosion were observed for the different blends[47,100]. This 
discrepancy may be related to structural differences resulting from the fabrication 
methods. Lee and associates made their devices by simply solvent casting, 
whereas in the present work, CAP/PF-127 microspheres were made first and 
then pressure-sintered into multilayered devices. Another reason for the different 
degradation rates may be the exposed surface area. Lee’s samples were 
exposed on both top and bottom surfaces, so the degradation rate was relatively 
higher compared to the present devices, which were coated to protect all but one 
surface from the aqueous environment. Differences in the carboxylate content of 
CAP obtained from different sources may also have affected material 
degradation.  
Directional control of release was obtained by coating with a more 
hydrophobic biodegradable polymer(PLGA). Poly Lactic acid(PLA) also can be 
considered as a coating materials, however the degradation rate of PLA is more 
than a year [101], consequently, PLA should be remained on the implant site for 
long period of time after CAP/PF-127 device degradation. It is not necessary that 
coating material remains on the implant site after delivery device degradation. 
Thus, only one surface was exposed to PBS, and as mentioned previously, the 
degradation rate was consequently reduced. The total duration of delivery 
depended directly on the number of layers and the release environment. For 
each additional set of blank and loaded layers, another release peak was 
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obtained. Even gentle mechanical agitation enhanced erosion of the polymer. 
These results indicate that, in addition to chemical dissolution effects, physical 
erosion also plays a role in degradation of CAP/PF-127. Therefore, even though 
intermittent release will be obtained, the duration of delivery will depend on the 
site of implantation. Consider, for example, low clearance of erosion byproducts 
following placement in a relatively confined bony defect compared to an implant 
more vigorously bathed in body fluids.  
Comparison of the present doses to those used clinically is complicated by 
the significantly different uses of simvastatin:  systemic lowering of cholesterol 
vs. stimulation of local bone formation.  The clinically recommended therapeutic 
dose of simvastatin ranges from 5 to 80 mg/day.  With 60 mg dosage forms, 
serum concentrations of simvastatin and simvastatin acid are 18.7 +/- 4.7 ng/ml 
and 3.5+/-0.5 ng/ml, respectively.  Further, the half-life of simvastatin acid is 5.9 
+/- 0.3 hr [56]. The devices described in the present work released simvastatin 
acid at a rate of approximately 36.5 ng/hr into 5 ml of PBS.  To stimulate bone 
formation in animals, Mundy et al. [1] injected 1-10 mg/kg/day subcutaneously 
over the calvaria of mice for 5 days.  Assuming 30 g animals, up to 
approximately 300 μg of simvastatin was administered each day.  In contrast, 
the present devices contained up to only 5 μg of simvastatin acid.   
As might be expected with many biodegradable/bioerodible materials, high 
levels of degradation byproducts can be cytotoxic. This has been well-
documented for polymers and copolymers of lactic and glycolic acid [102-105]. 
When biodegradable materials are implanted, however, the concentration of toxic 
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byproducts is reduced via dilution in extracellular fluids and blood and by 
clearance via the circulatory and lymphatic systems.  In the present work, 
although high concentrations of degradation products were cytotoxic, dilution of 
CAP/PF-127 byproducts to less than 40% prevented adverse effects.  
Preliminary results following implantation of CAP/PF-127 release devices in rats 
show no evidence of adverse effects (data not shown).   
The results of DNA content, AP activity, and OCN secretion for 
preosteoblastic cells exposed to intermittent and sustained concentrations of 
simvastatin acid at lower concentrations (100pM - 10nM) indicate an anabolic 
effect. The continued inhibition of HMG-CoA reductase activity and therefore of 
cholesterol synthesis resulting from high, sustained concentrations of simvastatin 
acid appear to have adversely affected the cells and prevented growth and 
activity.  After Mundy and colleagues [1] reported that simvastatin induced 
expression of BMP-2 in a model reporter system, Maeda et al. [51] showed that 
continuous low doses of simvastatin enhanced AP activity and mineralization and 
increased BMP-2 production in MC3T3E-1 cells.   
In the present work comparing alternating exposure with constant 
treatment, the former stimulated higher osteoblastic activity. This result is similar 
to that for Mundy’s delivery via subcutaneous injection and the resulting local 
pulsatile simvastatin profile that was found to enhance bone formation. Skoglund 
and associates delivered simvastatin by daily oral dosing and found that 
simvastatin-treated mice had a larger transverse area of fracture callus, and the 
force required to break the bone was greater than controls [2]. Many clinical 
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studies have suggested that statins are related to an increase in bone mineral 
density and significantly reduced fracture risk [106,107]. 
 
1.5   CONCLUSION 
Intermittent release of simvastatin acid was achieved using the association 
polymer system of CAP and PF-127. The release profiles roughly mimic local 
exposure resulting from repeated oral dosing or subcutaneous injections.  
Furthermore, the release profiles can be controlled by varying polymer blending 
ratio, number of layers, and release conditions. Cell number, alkaline 
phosphatase activity, and osteocalcin secretion were enhanced in preosteoblastic 
cell cultures treated with alternating concentrations of simvastatin acid.  
Ongoing studies are directed at evaluating the bioactivity of intermittently 
released simvastatin acid in vivo.  Overall, CAP/PF-127 devices can be 
designed to provide pulsatile release of simvastatin acid, and such alternating 
concentrations stimulate osteoblastic activity.  These devices may be useful for 
promoting local bone formation.  
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Chapter Two 
 
LOCALIZED INTERMITTENT DELIVERY OF SIMVASTATIN ACID  
STIMULATES BONE FORMATION IN VIVO 
 
2.1   INTRODUCTION 
Stimulation of local bone formation using pharmacological compounds 
that upregulate synthesis of autogenous bone growth factors is a promising 
approach to treatment of bone defects. This method can lead to cost-effective 
devices and less complicated surgeries [3].  Application of growth factors, 
including bone morphogenetic protein-2 (BMP-2), can powerfully stimulate bone 
formation. However, such recombinant proteins are expensive and when 
exposed to a physiological environment, they can be degraded rapidly [108]. 
Furthermore the supraphysiological amounts needed may cause immune 
responses [109].  
Simvastatin is a member of the statin family of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase competitive inhibitors, which are widely used 
as cholesterol-lowering drugs. Simvastatin promotes bone formation both in vitro 
and in vivo in animal models, associated with increased expression of BMP-2 
[48,51,110]. In addition, simvastatin inhibits mevalonate, farnesyl pyrophosphate, 
and geranylgeranyl pyrophosphate pathways [49,111,112], which are responsible 
for bone formation by reducing osteoclastic activity [50]. This inhibition 
mechanism plays an important role in the stimulation of bone mass by 
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simvastatin.  
Currently available simvastatin is chemically modified from naturally 
existing lovastatin. It has been developed for oral administration and to be 
hepatoselective to decrease cholesterol synthesis in the liver. When delivered via 
systemic circulation, simvastatin shows poor distribution to bone defect sites 
[110]. Consequently, developing a simvastatin delivery device that provides 
active amounts of drug with an appropriate time course to a desired site may be 
more biologically effective.  
Unlike traditional controlled release devices, which often aim to achieve 
zero-order kinetics for constant concentration in the plasma, subcutaneous 
injection and oral administration show pulsatile drug concentration profiles. In a 
previous paper, we developed a device for intermittent release of simvastatin acid 
using an association polymer system of cellulose acetate phthalate (CAP) and 
Pluronic F-127 (PF-127).  Pulsatile release profiles were demonstrated, and in 
vitro stimulation of preosteoblastic cell activity was shown [46].  
Based on prior results, the objective of the present study was to 
investigate the ability of devices for controlled, localized delivery of simvastatin 
acid, either with intermittent or sustained release, to stimulate localized bone 
formation in a rat calvarial onlay model.  
2.2   MATERIALS AND METHODS 
2.2.1   CAP/PF-127 Microspheres and Release Devices 
CAP/PF-127 microspheres and release devices were fabricated as 
reported previously [46] and are briefly described here. Drug-loaded 
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microspheres were made using a triple emulsion process to have a loading of 50 
ng simvastatin acid per mg of polymer. Intermittent release devices were then 
made by alternating 20 mg layers of microspheres loaded with simvastatin acid 
and blank microspheres (without drug) (Figure 2.1). Sustained release devices 
were made in the same manner, but every 20 mg layer contained simvastatin 
acid. Control (blank) devices were made with the same amount of microspheres 
used in sustained and intermittent release devices, however no drug was present. 
To provide directional control of drug release, the bottom and sides of all devices 
were coated with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa; Alkermes, 
Cincinnati, OH) solution in dichloromethane. To verify release profiles, devices 
were incubated in 150 mM phosphate-buffered saline at 37ºC with gently shaking, 
and simvastatin concentrations were determined fluorometrically [46]. 
 
2.2.2   Animal Procedures  
Two month old male Sprague-Dawley rats were used in this study. A 
calvarial onlay model was used to determine effects of local delivery of 
simvastatin acid. Blank (no drug) devices (n=10), intermittent devices (n=10), and 
sustained devices (n=10) were tested. After anesthetization, a transverse incision 
was made toward the posterior end of the skull. The periosteum was reflected, 
and implants were placed directly on the calvarium, with the exposed drug-
releasing side of the devices facing the bone. Incisions were closed with three 
sutures. 
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Figure  2.1. Schematic representation of intermittent (A) and sustained 
release devices (B).  
 
2.2.3   Histological Preparation 
After 9, 18, or 28 days, rats were euthanized, and the calvaria were 
harvested. Specimens were immediately stored in 10% buffered formalin 
phosphate (Fisher Scientific, Fair Lawn, NJ) solution for at least one week. 
Samples were decalcified overnight in 5% nitric acid, dehydrated in an alcohol 
series, and embedded in paraffin. Five μm thick coronal cross-sections were cut, 
before staining with hematoxylin for 15 minutes and eosin for 15 seconds to 2 
minutes then dehydrate in 95% absolute alcohols for transmitted optical 
microscopy evaluation. 
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2.2.4   Histological Analysis 
Representative sections from the control, sustained release, and 
intermittent release groups were examined at 40X and 100X magnification with 
an Olympus IX51 inverted microscope with Insight digital camera (Diagnostic 
Instruments, Sterling Heights, MI). In addition to qualitative assessments, the 
thickness and total area of newly formed woven bone, the thickness relative to 
implant center, and area percentage of lamellar bone islands within the woven 
bone layer were determined. Thickness measurements were made on at least six 
samples with 5 different regions in each group. Area calculations were based on 
examination of 3 different 1 mm2 spots from at least six samples in each group. 
ImageJ software (National Institutes of Health, Bethesda, MD) was used for 
quantification.  
2.2.5   Statistical Analysis 
Data are presented as mean ± standard deviation of up to nine 
measurements.  All histological measurements were compared among groups 
by analysis of variance (ANOVA) using InStat (Graphpad Software, San Diego, 
CA). Post-hoc comparisons were made using the Tukey-Kramer Comparison 
Test when the p-value was significant (p<0.05). 
 
2.3  RESULTS 
2.3.1   Release Profiles 
The approximate loadings of simvastatin acid were 5 μg for intermittent 
release devices (5 drug-loaded layers at 1 μg/layer) and 10 μg for sustained 
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release devices (10 loaded layers at 1 μg/layer).  Figure 2.2 shows profiles for 
release of simvastatin acid from the intermittent and sustained delivery devices.  
As expected from their design, intermittent release devices exhibited five discrete 
peaks separated by two to three days.  In contrast, for sustained release 
devices, the concentration of simvastatin acid increased over the first 24 hours 
and remained relatively constant for the next ten days. Both devices achieved 
similar maximum concentrations and lasted for comparable durations.  
 
2.3.2   Clinical and Physical Examination 
During the postoperative healing period, wound dehiscence occurred in 3 rats (1 
in each group), and infections resulting from bites from cage mates were 
observed in 3 rats (2 in blank group and 1 in sustained one). As a result, 7 control, 
9 intermittent, and 8 sustained specimens were available for histological analysis. 
All animals gained weight (up to 50 g) during the postoperative healing period (9-
28 days; data not shown).  
 
2.3.3   Histological Analysis 
Figure 2.3(A) shows the gross morphology of the implant site. At 9 and 
18 days, devices were surrounded by fibrous and inflammatory tissue. At 28 days, 
the amount of tissue was significantly reduced as the drug delivery component of 
the implants was degraded and the poly(lactic-co-glycolic acid) shell collapsed 
and began to disintegrate. In Figure 2.3(B), comparison of the three types of 
devices shows similar appearance after 28 days. In all groups, implants had 
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largely been degraded and some fibrous scar tissue was present at the surgical 
site.  
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Figure  2.2.   Comparison between the intermittent and the sustained 
release profiles for 10-layer devices . 
 
Figure 2.4 shows the bone-forming ability of released simvastatin acid. 
Much newly formed woven bone with islands of matrix stained more intensely 
with eosin and osteocytes were found on the calvarium. Furthermore, many 
blood vessels were generated in and around the new bone area.  
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Newly formed woven bone thickness was significantly different between 
the control simvastatin acid release groups (Fig. 2.5 and 2.6). Fibrous and 
inflammatory tissue was found above the newly formed bone. Intermittent release 
devices stimulated 133% greater woven bone thickness (187±40 µm) compared 
to control devices (80±30 µm) (p<0.05), and sustained release devices 
stimulated 77.5% greater woven bone thickness (142±56 µm) (p<0.05) compared 
to controls. Comparing the two release profiles, intermittent devices stimulated a 
32.3% greater response than did the sustained release (p<0.05). 
 
    9 days  28 days  28 days        Control  Sustained  Intermittent 
 (A)                               (B) 
 Figure  2.3.   Gross morphological state of tissues (A) around sustained 
release devices at different healing times (9, 18, and28 days) and (B) 
around different devices after 28 days. 
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Figure  2.4.   Representative photomicrograph showing the formation of 
woven bone (W), lamellar bone (L), osteocytes (O), and blood vessels (B) 
above the calvarium (C).   
Woven bone thickness varied from implant center to periphery, as shown 
in Figure 2.7 The site directly below the device showed minimal woven thickness 
(18.8-36±7.6-40 µm) compared to other locations (44-205.1±6.53-38.5 µm) 
(p<0.05). Figure 2.8 shows the total area of new bone and the percentage of 
more intensely stained matrix relative to total bone. Intermittent release groups 
elicited 162.7% larger new bone area and sustained delivery stimulated 74.1% 
more new bone area than did control implants. The percentage of intensely-
stained bone matrix for the intermittent (25.5%) and sustained groups (24.8%) 
was higher than that for the controls (21.3%) (p<0.05). Comparing alternating 
 41
and sustained groups, although the alternating group was slightly higher, the 
difference was not statistically significant. 
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Figure  2.5.   Represenative photomicrographs comparing new bone 
formation above the calvarium in all experimental groups.    
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Figure  2.6.   Thickness of newly formed woven bone over calvariae 
treated with control, sustained release, and intermittent release devices.  
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Figure  2.7.   Thickness of newly formed bone according to distance from 
implant/calvarium center (- Left/+ Right). 
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Figure  2.8.   Total area of new bone and percentage of lamellar bone. 
 
2.4   DISCUSSION 
The present results demonstrate that locally released simvastatin acid 
stimulated supracalvarial bone growth. Osteogenesis was enhanced by both 
intermittent and sustained delivery.   
All specimens showed signs of inflammatory responses up to 18 days. 
Newly formed woven bone was found in controls animals implanted with blank 
(drug-free) devices as well as in those in the sustained and intermittent release 
groups. Inflammatory responses on bone formation are related to cytokine 
mediators, which influence cells locally to change remodeling activities 
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associated with appositional bone growth [113-115]. Accordingly, inflammatory 
responses may be one of the main contributions to formation of new bone found 
in all groups, with localized release of simvastatin acid enhancing the effects.  
Even though the studies were not intended to quantitatively assess 
angiogenesis, it is interesting to note that many newly formed blood vessels were 
found in around the woven bone in all groups. However the simvastatin treated 
groups had a higher degree of angiogenesis than control groups (data not 
shown). These blood vessels likely increased blood flow in and around the 
implantation site and expedited new bone formation. It was reported by Kureishi 
et al. that simvastatin acid administration promotes new blood vessel growth [52].  
The newly formed bone was composed of large areas of woven bone 
intermixed with areas of lamellar bone.  These islands were identified by their 
greater organization and differential staining, with the more mature bone staining 
more intensely.  It is thought that an appositional growth occurred as layers of 
bone were formed over the existing calvarium, resulting in overall bone growth 
[116], similar to what is observed during intramembranous ossification.  Even 
though new bone thicknesses stimulated by the intermittent release devices was 
highest and for the control devices was lowest, the morphology of newly formed 
bone and presence of islands of lamellar bone in all three groups were 
analogous.  However, the slightly higher percentage lamellar bone stimulated by 
both types of drug-containing devices suggests that simvastatin acid delivery 
stimulated bone formation and bone maturation. 
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The present results are in accordance with previous reports of simvastatin 
delivered via injection in mice. Mundy’s’ group subcutaneously injected three 
different doses (1, 5, or 10 mg/kg/day, which would be 30, 150, or 300 µg/day for 
a 30 g mouse) of simvastatin for 5 days, and reported increases in total bone 
area of 2, 20, and 46%, respectively [1]. In other studies, treatment with low 
doses of simvastatin increased cancellous bone volume and the transverse area 
of fracture callus.  Our release devices had alternating five or ten simvastatin-
loaded layers and intermittently or continuously delivered 1 µg/layer for no more 
than 12 days, yet they promoted bone formation to either a 74% (sustained) to 
163% (intermittent) increase in bone area.  It is thought that the present devices 
would be a candidate for localized bone formation as well as or better than 
subcutaneous injections.   
A limited number of groups have investigated materials for localized 
delivery of simvastatin [3-5,117].  Thylin et al. injected simvastatin mixed into 
methylcellulose gel [5].  They reported an optimal does of 2.2 mg simvastatin 
yielding up to 170% increase in calvarial thickness.  “Extensive” leakage of the 
gel from the injection site was noted for some animals.  Simvastain (crushed 
Zocor tablets) has also been mixed with absorbable collagen and implanted into 
rabbit calvarial defects [118]. A dose of 0.5 mg simvastatin per 0.2 g collagen 
sponge stimulated filling in the defects, but the kinetics of drug release were not 
studied.  A reservoir system with methylcellulose gel containing 0.1-2.2 mg of 
simvastatin under a biodegradable poly(lactic acid) membrane enhanced bone 
formation by 45% on the rat mandible, but considerable inflammation occurred 
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[3].  Although not tested in vivo, other approaches to delivering simvastatin 
include incorporation in hydroxypropylmethyl cellulose, sodium carboxymethyl 
cellulose, and chitosan for short term (approximately 6 hr) release [117] and 
attachment to poly(lactic-co-glycolic acid) for extended retention of the drug 
[119,120] . The intermittent and sustained release devices described in this paper 
had approximate totals of 5 µg and 10 µg simvastatin acid, respectively, and they 
stimulated 78% (sustained) to 133% (intermittent) increased bone thickness 
compared to control groups.  
 In previous work, the drug delivery component of the implants was totally 
degraded within two weeks in vitro, but the PLGA membrane used for controlling 
directionality of simvastatin acid release remained in the sample solution [46]. 
Depending on the ratio of lactic acid to glycolic acid, PLGA degradation rates 
vary from 1 to 6 month [121]. Due to the large difference in degradation times for 
CAP/PF-127 and PLGA, even though the CAP/PF-127 drug release component 
was entirely degraded, some degree of fibrous and inflammatory tissue 
surrounded the remaining PLGA fragments after 28 days.  
 Diffusion of released simvastatin acid to peripheral tissues increased new 
bone thickness at the edges of the calvariae. Mechanical and/or chemical effects 
may have resulted in minimal bone formation directly under the devices. For 
example, relative motion between implant and bone may have occurred during 
daily activities of the animals, and locally concentrations of CAP/PF-127 erosion 
products would have been higher directly under the devices.  To achieve a more 
even layer of new bone, additional space may be required directly under the 
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implant. Placement of the drug delivery device in conjunction with a 
biodegradable scaffold or other space-making implant could alleviate the 
nonuniformity. Alternatively or in addition, the implant may be protected from 
movement immediately following placement.   
 
2.5   CONCLUSION 
Using a multilayering method, devices for localized delivery of CAP/PF-127 
were fabricated. Alternating release devices showed five discrete peaks, while 
sustained release devices showed zero-order release for approximately ten days. 
Based on our experimental results, local delivery of simvastatin acid with either 
sustained or intermittent release profiles stimulated formation of new bone in vivo. 
Furthermore, the intermittent devices were more effective than sustained devices, 
while requiring only one half the amount of drug.  
 
 
 
 
 
 
 
 
 
Copyright © Ju Hyeong Jeon 2007 
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Chapter Three 
 
INTERMITTENT RELEASE OF PARATHYROID HORMONE (1-34) 
BIODEGRADABLE DEVICE ENHANCES OSTEOBLASTIC ACTIVITIES  
 
3.1   INTRODUCTION 
Parathyroid hormone (PTH) is well known for its role in calcium 
homeostasis. The N-terminal fragment comprising the first 34 amino acids, 
PTH(1-34), has biological activity comparable to the whole molecule. It has been 
reported that daily injections of low doses of PTH or PTH(1-34) stimulate bone 
formation and increase bone mass in humans and animals [7,12,14,60-63]. Many 
in vivo studies have been conducted to explain the anabolic effect of PTH or 
PTH(1-34) on bone formation, and experiments with intermittent infusion and 
injection of PTH(1-34) have shown increased bone mass [26]. It is thought that 
PTH increases bone formation by decreasing the apoptosis of osteoblasts [11], 
whereas continuous administration of PTH or PTH(1-34) result in decreased 
bone mass [15,64,122]. These results imply that the effects of PTH on bone cells 
vary with cell type and experimental conditions, such as intermittent or 
continuous administration [10]. Many in vitro studies have been conducted to 
determine PTH effects on bone. From the results, it is clear that PTH enhances 
proliferation of primary osteoblastic cells from humans and animals [65,66]. In 
addition, PTH exerts diverse effects on osteoblast differentiation depending on 
differentiation stage [123,124].  
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To mimic the effect of injections, devices need to provide intermittent 
release profiles. We previously investigated an association polymer system 
based on blends of cellulose acetate phthalate (CAP), which is a well known 
enteric coating material in the pharmaceutical industry, and a nonionic surfactant, 
Pluronic F127 (PF-127), which is used for stabilizing proteins and peptides during 
lyophilization. The CAP/PF-127 polymer system is useful for programmed drug 
delivery, with the rate, duration, and amount of released drug controlled by 
thickness, blending ratio, and number of layers [16,47].  
The objective was to develop devices for intermittent release of PTH(1-34) 
and to determine the effects of PTH(1-34) released with different profiles on 
osteoblastic cellular activity. Our hypothesis was that the mode of local PTH(1-
34) release affects osteoblastic activity. To verify this hypothesis, in this study, 
devices for intermittent delivery of PTH(1-34) were developed, and it was 
demonstrated that the cellular effects of PTH(1-34) on osteoblastic proliferation 
and differentiation were dependent on mode of administration. 
 
3.2   MATERIALS AND METHODS 
3.2.1   CAP/PF-127 Microspheres and Release Devices 
PTH(1-34) (Bachem, Torrance, CA) was labeled with Alexa Fluor 350 
Carboxylic acid, succinimidyl ester (Invitrogen, Eugene, OR) to enable 
measurement of the released amount. CAP (Fluka, Buchs, Switzerland) and PF-
127 (Sigma, St Louis, MO) microspheres were made by a water-acetone-oil-
water (W/A/O/W) triple emulsion process. CAP and PF-127 polymer blend (7:3 
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weight fraction of CAP and PF-127) was dissolved in acetone. To this acetone 
solution, phosphate-buffered saline (PBS), pH 7.4, with 0 or 250 μg/ml of CB 
were added and then homogenized into corn oil and sonicated for 20 seconds. 
The CAP/PF-127 suspension and 5% Triton X-100 solution were added to 
deionized water and then stirred to harden the microspheres for 5 minutes. 
Following collection, microspheres were washed, filtered, and lyophilized 
overnight.     
Release devices were made using a pressure-sintering process. Fifteen to 
20 mg of UV-sterilized microspheres containing PTH (1-34) were placed in the 
wells of a Delrin mold (diameter, 6.2 mm; depth, 20 mm) and consolidated by 
applying 20 MPa pressure for 5 sec. Next, for intermittent devices, blank 
microspheres were added on top of the first layer, and pressure was reapplied. 
By repeating this process, ten-layer devices were prepared. For sustained 
release devices, all layers were composed of microspheres containing PTH(1-34).  
To provide directional control of drug release, the bottom and sides of the devices 
were coated three times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 
kDa; Alkermes, Cincinnati, OH) solution in methylene chloride.  
3.2.2   In Vitro Release  
Devices were immersed in 5 ml PBS, pH 7.4, and incubated at 37ºC.  
One ml of supernatant was collected and the remaining PBS replaced daily. To 
allow quantification of released PTH(1-34), CAP was precipitated from the 1 ml of 
supernatant by treatment with 50 μl of 0.1 M hydrochloric acid. Acid-treated 
supernatants were then centrifuged at 1000 rpm for 5 minutes. Solutions were 
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placed into 96-well assay plates, along with labeled PTH(1-34) standards made 
by serial diluting from a 100 ng/ml stock solution. The concentrations of labeled 
PTH(1-34) were determined fluorometrically using a SpectraMAX Gemini XS® 
(λex=346 nm, λem=442 nm). In order to investigate pH changes, devices were 
immersed in 5 to 15 ml PBS at 37ºC, and the pH was measured each day.  
3.2.3   Cell Culture  
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manassas, VA) were 
seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α-Minimum 
Essential Medium (MEM) containing 10% fetal bovine serum (GIBCO/Invitrogen, 
Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ß-glycerophosphate 
(Sigma),and antibiotics (penicillin G and streptomycin GIBCO ), and 0-5 ng/ml 
PTH(1-34). In sustained release cultures, one set of cells was constantly 
exposed to various PTH(1-34) at a fixed concentration.  In intermittent release 
cultures, another set was exposed to alternating concentrations. In control 
cultures, medium was changed on the same schedule, but it did not contain 
PTH(1-34).  
3.2.4   In Vitro Bioassays 
After 3, 7, 10, and 14 days of culture, cells were harvested and then lysed 
by sonication in high salt solution (0.05M NaH2PO4, 2M NaCl, and 2mM EDTA). 
DNA standards were prepared by serial diluting calf thymus DNA in the high salt 
solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was added to 
DNA standards and samples and allowed to react in the dark for 10 minutes [125].  
The amount of DNA in the samples was determined by measuring fluorescence 
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(λex=356 nm, λem=458 nm).   
To measure alkaline phosphatase (AP) activity, lysed cell samples were 
incubated with substrate solution prepared by dissolving 10 mM of Sigma 104 
phosphatase substrate in Sigma 221 alkaline buffer solution. After 30 minutes, 
0.25 N NaOH was added to each well to immediately stop enzyme activity. 
Absorbance at 410 nm was measured with an MR5000 microplate reader 
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was 
determined using ε=1.7x104 M-1cm-1.  Activity was expressed as nM of substrate 
cleaved per minute and then normalized by DNA content.  
For measuring osteocalcin (OCN) secretion, conditioned medium collected 
from cultures samples was assayed using an EIA kit (Biomedical Technologies, 
Stoughton, MA) following the manufacturer’s protocol.  Concentrations were 
determined from a standard curve constructed using mouse OCN.   
3.2.5   Statistical Analysis 
Results (mean and standard deviation) were calculated from at least six 
replicate samples. One-way analysis of variance (ANOVA) was conducted using 
the computer application InStat (Graphpad Software, San Diego, CA). Post-hoc 
comparisons were made using the Tukey-Kramer test when the p-value was 
significant (p<0.05).   
 
3.3  RESULTS 
3.3.1  Release Profiles and Sample pH  
The CAP/PF-127 polymer degraded by erosion at the one surface 
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exposed to the aqueous environment. In Figure 3.1, device weight and thickness 
were decreased linearly at the rate of 11.5 mg/day-15.4 mg/day over the period 
of the experiments, as expected from zero-order kinetics.    
Intermittent release profiles were achieved by alternately layering PTH(1-34)-
loaded microspheres and blank (unloaded) microspheres. Figure 3.2 shows both 
intermittent and sustained release profiles for 10-layer devices. With sustained 
release devices, the amount of released PTH(1-34) gradually increased over the 
first 3 days, and afterward the amount of delivered PTH(1-34) remained relatively 
constant and showed a zero-order release profile. In contrast, intermittent 
release devices provided five discrete peaks, each separated by 2-3 days. Figure 
3.3 shows cumulative release of PTH(1-34) from intermittent and sustained 
release devices. Sustained release devices were composed of 10 PTH(1-34)-
loaded layers, but intermittent release devices were fabricated with 5 PTH(1-34)-
loaded and 5 blank layers. Consequently, the total amount of PTH(1-34) released 
from intermittent release devices was close to half that from sustained release 
devices (p<0.05). 
Figure 3.4 shows the pH in intermittent release samples at each day. All 
devices in various amounts of PBS were degraded in 13 days, as also shown in 
the previous figure. When devices were immersed in 5, 10, and 15 ml of PBS, 
the ranges of pH of samples were 6.64 - 6.88, 6.76 -6.91 and 7.05-7.24, 
respectively. For samples incubated in 10 and 15 ml PBS, pH was more stable 
through out the degradation period compared to those incubated in 5 ml, but at 
day 13, pH was 0.15-0.19 lower than any other period (p<0.05). 
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Figure  3.1.  Device thickness and weight changes during degradation of 
10-layer release devices.  
 
3.3.2  Effect of Alternating or Constant Concentrations of PTH(1-34) on 
Osteoblastic Cells 
       In order to determine proper levels of PTH(1-34) release from the 
devices and to investigate effects of concentration, and mode of exposure to 
PTH(1-34), cell responses were investigated. Results for DNA contents in 
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MC3T3-E1 cultures exposed to intermittent or sustained delivery of PTH(1-34) 
are shown in Figure 3.5. At day 3, DNA contents in osteoblast cultures treated 
with both sustained and alternating concentrations of PTH(1-34) were 64-86% 
higher than in controls (p<0.05). At day 7, all groups except the sustained 500 
pg/ml showed their highest DNA contents (p<0.05) during culture, however levels 
in the 5 ng/ml alternating group were slightly higher than the others. At day 10, all 
groups except the 500 pg/ml sustained showed a slight decrease in DNA content 
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Figure  3.2.  Instantaneous release of PTH(1-34) from 10-layer intermittent 
and sustained release devices.  
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Figure  3.3.  Cumulative release of PTH(1-34) from 10-layer intermittent 
and sustained release devices.  
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Figure  3.4.  Daily pH in sample solution during degradation of 10-layer 
devices. 
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, with a decrease for the 5 ng/ml sustained group. At day 14, both alternating and 
sustained 5 ng/ml groups had similar DNA contents as 10 days, while other 
groups had decreased levels.  
AP activity in PTH(1-34)-treated cultures is shown in Figure 3.6. At day 3, 
AP activity was 50-106% higher in PTH(1-34)-treated cultures compared to 
controls (p<0.05). At day 7, all groups showed increased AP activity except 500 
pg/ml sustained. At day 10, all groups showed their highest AP activity, while at 
day 14, all groups showed decreased AP activity. AP activity in cultures exposed 
to 5 ng/ml alternating PTH(1-34) had the largest decrease compared to other 
groups. Cells treated with alternating levels of 5 ng/ml PTH(1-34) showed the 
highest overall activity at day 10.  
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Figure  3.5.  DNA content in cultures exposed to sustained and 
intermittent PTH(1-34). 
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In Figure 3.7, all experimental groups showed increased OCN contents 
compared to control groups (p<0.05). At day 1, there was no significant 
difference in OCN secretion between sustained and alternating groups in the 
same concentration, but from days 2 to 10, cultures treated with alternating levels 
of PTH(1-34) stimulated significantly greater (14-267%) osteocalcin secretion 
compared to cells constantly treated with the same concentration (p<0.05). 
Cultures exposed to alternating PTH(1-34) showed increasing OCN secretion 
through the period of culture (10 days), but OCN secretion in cultures treated 
with constant concentrations of PTH(1-34) plateaued earlier (by 6 days).  
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Figure  3.6.  AP activity in cultures exposed to sustained and intermittent 
PTH(1-34). 
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Figure  3.7.  Osteocalcin secretion for osteoblasts exposed to sustained 
and intermittent PTH(1-34).  ??did you check statistics for sus groups at 4 
and 6 days?? 
 
3.4  DISCUSSION 
Blends of CAP and PF-127 form an association polymer that undergoes 
surface erosion and shows zero-order release [16,46]. A number of ether sites in 
PF-127 and carboxylic acid groups in CAP form hydrogen bonds. When these 
hydrogen bonds are exposed to aqueous solution, carboxyl groups start to 
deprotonate, and the material degrades. The deprotonation makes the 
surrounding solution acidic. Acidic conditions can have adverse effects on bone 
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and bone cells. Decreasing pH reduces expression of ALP and OCN in bone 
marrow stromal cells [126]. In particular, pH below 6.6 caused two- to three-fold 
decreased ALP expression. Another group showed that acidic conditions up-
regulates PTH/PTHrP receptors in osteoblast-like cells [127]. In order to prevent 
local acidosis, and reduced ALP and OCN expression, pH at the site of a 
degrading CAP/PF-127 implant should be kept above 6.6 [128]. Our samples had 
slightly acidic pH, down to 6.64 when incubated in the smallest volume of PBS. In 
larger volumes, release supernatants were nearly neutral. Continuous clearance 
of degradation products in vivo would be expected to minimize pH changes. 
Preliminary studies in a rat model did not show adverse effects.  
 By modifying surface area, layer thickness, and alternatingly loading 
layers in the devices, PTH(1-34) release can be controlled. Unlike the cumulative 
release profile of sustained release devices, alternating devices showed 
relatively flatter regions, which reflect erosion of unloaded layers. Directional 
control of delivery was provided by coating with a more hydrophobic 
biodegradable polymer, in this case poly(lactide-co-glycolide). Thus, only one 
surface was exposed to PBS. Theoretically, the lowest points in the intermittent 
release profiles should have reached zero PTH(1-34) because the blank layers 
did not contain peptide. However, low but measurable concentrations were 
detected. It is believed that when fabricating the multilayered devices, some 
microspheres adjacent to loaded and blank layers became intermingled under 
pressure and sampling interval also affect to the result. Our devices were even 
10 layer device with 13 day of degradation time. Ideally, sampling interval should 
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have been 1.3 day or more frequent sampling such as 3 times or 4 times a day. 
By 1 day sampling interval, we can closely calculate the trend of release profile of 
the devices but somewhat difficult to figure out exact release profile. 
    The plasma half life of intact PTH(1–34) is less than 11 min [36]. The fast 
metabolic degradation of PTH requires multiple administrations of PTH 
necessary to keep the effective concentration in the plasma [78]. Normally, the 
physiological PTH level in plasma is 500 +/- 30 pg/ml, and there is no significant 
difference according to age or sex [129]. Our work provided a maximum 20 times 
higher PTH(1-34) concentration. The release devices were not intended for 
systemic delivery but for local delivery. Encapsulated PTH(1-34) can be protected 
from degradation factors, such as oxidization, water, and enzymes, until released 
from devices and then it is available to travel a short distance to the target area. 
Consequently, local delivery of PTH(1-34) enables enhancement of osteoblastic 
activity and bone formation with smaller amounts of PTH(1-34) compared to 
systemic delivery of PTH(1-34).   
Many approaches to intermittent PTH delivery have been investigated, 
such as injections, oral dosing, pulmonary inhalation, and transdermal delivery 
[35-41]. Most of these studies are focusing on systemic delivery for treatment of 
osteoporosis, whereas relatively few studies have looked at local delivery of 
PTH(1-34) for repair of focal bone defects. Pulmonary inhalation of 18-20 µg 
PTH(1-34) gave a plasma concentration of approximately 45 ng/ml, but the 
duration was less than 120 min [41]. Consequently, continuous inhalations were 
required for achieving and maintaining effective concentrations. PLGA 
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microspheres incorporating PTH(1-34) were developed for local delivery [78]. 
Although the microspheres sustained delivery of the peptide for more than 11 
weeks, it is difficult to achieve pulsatile release with this system.  Recently, Liu 
et al. described a system for pulsatile delivery of PTH(1-34) [35]. PTH(1-
34)/alginate films were alternated with polyanhydride layers inside a PLLA 
container. Release profiles showed 4 sharp peaks, with PTH(1-34) 
concentrations of 40-65 ng/mL, over a period of 4 days. Our devices provided 5 
discrete peaks with PTH(1-34) concentrations of 21-41 ng/ml for 12 days.   
Comparing alternating and sustained exposure to the same PTH(1-34) 
concentration, intermittent exposure stimulated higher osteoblastic activity. This 
could be expected, because continuous exposure down-regulates expression of 
its receptor in target cells [130,131]. PTH at physiological concentration is a 
potent suppressor of osteoblast differentiation; it is thought that PTH  prevents 
differentiation of preosteoblasts into osteoblasts [132]. The results in these 
studies correspond to our bioactivity results.  
 
3.5  CONCLUSION 
This work describes devices for local intermittent, delivery of PTH(1-34) 
without injection. By alternatingly loading microspheres with and without PTH(1-
34), intermittent release of PTH(1-34) was achieved using the association 
polymer system of CAP and PF-127. A slightly acidic condition that comes from 
erosion of the polymer may up-regulate expression of PTH receptors in cells. In 
vitro bioactivity experiments showed that either intermittently or sustained 
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exposing osteoblastic cells to PTH(1-34) enhanced their activity, but intermittent 
exposure resulted in enhanced cellular activity. These devices warrant further 
development for enhancing localized formation of bone.  
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Chapter Four 
 
ALTERNATING RELEASE OF DIFFERENT BIOACTIVE MOLECULES 
 
4.1  INTRODUCTION 
Controlled release technology enables delivery of a variety of 
biomolecules at the proper time, in the appropriate amount, and to the desired 
site. Most commonly, investigators seek to release one drug at constant 
concentrations for extended periods.  However, such zero-order kinetics can be 
undesirable.  For example, parathyroid hormone (1-34) (PTH(1-34)) can have 
either anabolic or catabolic effects on bone, depending on the mode of delivery. 
Daily administration of low doses of PTH stimulates bone formation and 
increases bone mass in humans and animals in vivo [7,12,14], and it enhances 
proliferation of primary osteoblastic cells [61,62] and diverse effects on osteoblast 
differentiation depending on differentiation stage [14,63]. In contrast, continuous 
administration of PTH has a catabolic effect  [8,9,15,64].  
Simvastatin (Sim), a member of the statin family of drugs know for 
lowering serum cholesterol, also has been reported to stimulate bone formation 
[1]. According to Mundy’s group, treatment of cell cultures with Sim induced 
expression of bone morphogenetic protein 2 (BMP-2), and daily subcutaneous 
injections of Sim stimulated bone formation on the calvaria of mice. Other studies 
showed that oral dosing with simvastatin increased cancellous bone volume in 
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rats [51], and it also increased transverse area of fracture callus as well as 
mechanical properties compared to controls [2].  
Regeneration of bony defects can be complex and involves sequential 
cascades of events [80]. Furthermore, these sites may face the threat of 
microbial infection, especially compound fractures and periodontal lesions. 
Infections in bony sites can be difficult to treat. Treatment may require multiple 
surgeries, prolonged antibiotic treatment, and long-term complications. Therefore, 
every effort is required to prevent this problem with early treatment [81]. Cecropin 
B (CB) is a naturally occurring cationic, amphipathic peptide derived from moths 
that has broad spectrum activity against not only certain gram-positive bacteria 
but also gram-negative bacteria, fungi, and parasites [84-86]. CB has an EC50 
(half maximal effective concentration) from 4 to 80 µg/ml, depending on the 
microorganism [86,90,91].  
Currently, therapies for tissue regeneration in the body mainly rely on the 
delivery of single biomolecules. Microspheres, nanospheres, and porous 
scaffolds comprised of numerous polymers, such as polylactides, polyglycolides, 
poly(lactide-co-glycolides), polyanhydrides, and polyorthoesters, have been 
developed for delivery of one biomolecule at a time [21-24,41,78,133,134], but 
few studies have been consulted with multiple biomolecules [92,93,135,136]. 
However, multiple signals are required to drive the regeneration process to 
completion in a timely and efficient manner, and consequently the success of 
current efforts releasing a single biomolecule to the defect site may be limited 
[92]. An approach to overcome limitations of single molecule delivery is release 
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of multiple molecules with distinct kinetics to trigger the desired tissue responses.  
In previous studies, we developed a controlled release system based on 
blends of cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) for 
intermittent release of small and large biomolecules [16,46]. The CAP/PF-127 
polymer system can be used for programmed drug delivery, with the rate, 
duration, and amount of released drug controlled by blending ratio, number of 
layers, and thickness [16,46,47]. The objective of this research was to further 
develop the CAP/PF-127 system for alternating delivery of multiple biomolecules 
and to investigate effects on osteoblastic cells.   
 
4.2  MATERIALS AND METHODS 
4.2.1  CAP/PF-127 Microspheres  
Cecropin-B (Anaspec, San Jose, CA) and PTH(1-34) (Bachem Torrance, 
CA) were labeled with Alexa Fluor 350 Carboxylic acid, succinimidyl ester 
(Invitrogen, Eugene, OR) and Alexa Fluor 488 Carboxylic acid, succinimidyl ester 
(Invitrogen), respectively, to enable measurement of the released amounts. CAP 
(Fluka, Buchs, Switzerland) and PF-127 (Sigma, St Louis, MO) microspheres 
were made by a water-acetone-oil-water (W/A/O/W) triple emulsion process. 
CAP and PF-127 polymer blend (7:3 weight fraction of CAP to PF-127) was 
dissolved in acetone. One ml of phosphate-buffered saline (PBS), pH 7.4, 
containing CB (250 or 500 μg/ml), PTH(1-34) (50 or 100 μg/ml), or Sim (420 or 
840 μg/ml; Aldrich, Milwaukee, WI) was added to the polymer solution, 
homogenized into corn oil, and then sonicated for 20 seconds. The CAP/PF-127 
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suspension and 5% Triton X-100 solution were added to deionized water and 
then stirred for 5 minutes to harden the microspheres. Following collection, 
microspheres were washed, filtered, and lyophilized overnight. 
4.2.2  Release Devices  
Release devices were fabricated using a pressure-sintering process and 
consolidated in acetone vapor. The first layer of CB/Sim and CB/PTH devices 
was made with 20 mg of mixed UV-sterilized microspheres (10 mg of each type). 
They were then placed in the wells of a Delrin mold (diameter, 6.2 mm; depth, 20 
mm) and consolidated by applying 20 MPa pressure for 5 sec. Next, 
microspheres containing only CB were added on top of the first layer, and 
pressure was reapplied. The third layer consisted of only Sim-containing 
microspheres for CB/Sim release devices or PTH-loaded microspheres for 
CB/PTH devices. Ten-layer devices were made by repeatedly alternating CB and 
Sim or PTH(1-34). Sim/PTH release devices were made by alternating layers of 
PTH- and Sim-containing microspheres.   
Figure 4.1 depicts the design of the three devices.  To provide directional 
control of drug release, the bottom and sides of the devices were coated three 
times with 10% poly(lactic-co-glycolic acid) (75:25, Mw~75 kDa; Alkermes, 
Cincinnati, OH) solution in methylene chloride.  
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Figure  4.1.  Schematic representation of (A) CB/Sim and CB/PTH devices 
and (B) Sim/PTH devices. 
 
4.2.3  Characterization of Microspheres  
Drug content was determined by dissolving 100 mg of microspheres in 5 
ml of PBS followed by precipitation of CAP in the solution with 50 μl of 0.1 M 
hydrochloric acid.  After centrifugation at 190 G-force (g) for 5 minutes, samples 
were placed into 96-well assay plates, along with solutions of Sim, fluorophore-
labeled CB, and fluorophore-labeled PTH. Each standard was made by serial 
diluting from a known stock solution. The concentrations of released Sim, CB, 
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and PTH(1-34) were determined fluorometrically using a SpectraMAX Gemini 
XS (PTH(1-34): λex=346 nm, λem=442 nm; CB: λex=495 nm, λem=519 nm; and 
Sim: λex=390 nm, λem=413 nm). Mean diameter of microspheres was measured 
using a Partica LA-950 Laser Diffraction Particle Size Analyzer. 
4.2.4  In Vitro Release 
Samples were immersed in 5 ml of PBS, pH 7.4, and incubated at 37ºC. 
Supernatant was collected and replaced daily to maintain a constant volume. To 
allow quantification of released biomolecules, CAP was precipitated from the 
supernatant by treatment with 50 μl of 0.1 M hydrochloric acid, and fluorescence 
was measured as described in the previous section. In order to investigate pH 
changes, devices were immersed in 15 ml PBS at 37ºC, and the pH was 
measured each day.  
4.2.5  Cell Culture 
MC3T3-E1 preosteoblastic cells (CRL-2593; ATCC, Manasas, VA) were 
seeded at a density of 15,000/cm2 into 24-well tissue culture plates in α-Minimum 
Essential Medium (MEM) containing 10% fetal bovine serum (GIBCO/Invitrogen, 
Carlsbad, CA), 50 µg/ml ascorbic acid (Sigma), 5 mM ß-glycerophosphate 
(Sigma), 1 μg/ml CB, 100 pM-1 µM Sim, and 500 pg/ml-50 ng/ml PTH(1-34). In 
CB/Sim, CB/PTH, and Sim/PTH release cultures, one set of cells was 
alternatingly exposed to CB and Sim, CB and PTH, and Sim and PTH(1-34), 
respectively. In control cultures, medium was changed on the same schedule, but 
it did not contain biomolecules. 
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4.2.6  DNA and AP Assays 
After 3, 7, 10, and 14 days of culture, cells were harvested and then lysed 
by sonication in high salt solution (0.05M NaH2PO4, 2M NaCl, and 2mM EDTA). 
DNA standards were prepared by serial diluting calf thymus DNA in the high salt 
solution. Hoechst 33258 (final concentration, 0.5 µg/ml; Sigma) was added to 
DNA standards and samples and allowed to react in the dark for 10 minutes [98]. 
DNA content of the lysates was quantified by measuring fluorescence (λex=356 
nm, λem=458 nm).  
Alkaline phosphatase (AP) activity was determined by a colorimetric assay. 
Lysates were incubated with substrate solution prepared by dissolving 10 mM of 
Sigma 104 phosphatase substrate in Sigma 221 alkaline buffer solution. After 30 
minutes, 0.25 N NaOH was added to each well to immediately stop enzyme 
activity. Absorbance at 410 nm was measured with an MR5000 microplate reader 
(Dynatech Laboratories, Chantilly, VA), and the amount of substrate cleaved was 
determined using ε=1.7x104 M-1cm-1.  Activity was expressed as nM of substrate 
cleaved per minute and then normalized by DNA content.  
4.2.7  Statistical Analysis 
All data were analyzed by analysis of variance (ANOVA) using the 
computer application InStat (Graphpad Software, San Diego, CA). Post-hoc 
comparisons were made using the Tukey-Kramer Comparison Test when the p-
value was significant (p<0.05). 
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 4.3  RESULTS 
4.3.1  Characterization of Microspheres  
Drug content and encapsulation efficiency of three different biomolecule-
containing microspheres are shown in Table 1. Drug content per g polymer and 
encapsulation efficiencies of CB, Sim, and PTH(1-34) microspheres were 11.2, 
85.1, and 111 μg and 53.1(p<0.05), 47.2(p<0.05), and 39%(p<0.05), respectively. 
As shown in Table 2, the mean size of blank, CB-, Sim-, and PTH(1-34)-loaded 
microspheres was 104, 161, 141, and 159 μm, respectively. Compared to blank 
microspheres, CB, Sim, and PTH(1-34) microspheres were 56.3% (p<0.05), 
37.3% (p<0.05), and 54.4%(p<0.05)  respectively, larger in mean size.  
 
Table  4.1.  Drug content and encapsulation efficiency for the three types 
of microspheres.  
 
Initial 
CAP/PF-127 
(g) 
Drug 
Added 
(μg) 
M.S. 
Harvested (g) 
/ Yield (%) 
Total Drug 
Content (μg) / 
E.E.* (%) 
Drug Content 
per g polymer 
(μg) 
PTH 1.4/0.6 = 2  50  
1.654±0.124 / 
82.7 ±7.5 
24.6±9.1 / 
39±36.9 
11.2 
Cecropin B 1.4/0.6 = 2  250  
1.563 ±0.215 
/ 78.2 ±13.7 
132.8±17.5 / 
53.1±13.1 
85.12 
Simvastatin 1.4/0.6 = 2  420  
1.788 ±0.298 
/ 89.4 ±16.7 
198.6±18.7 / 
47.2±9.4 
111.1 
* encapsulation efficiency.  Data are the mean of four replicates 
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Table  4.2.  Sizes of the three types of microspheres.   
Refractive Indices : D.I. water, 1.333; CAP, 1.475. Data are the mean of four replicates  
 Blank Cecropin B PTH Simvastatin 
Mean Size (μm) 103.92 161.16 159.08 141.18 
Median Size (μm) 117.72 168.87 184.34 123.245 
Std. Dev (μm) 67.894 113.31 90.161 89.848 
 
4.3.2  Sample pH and Release Profiles   
Figure 4.2 shows the pH at each day for the three different devices 
developed. CB/PTH devices were degraded in 15 days, and CB/Sim and 
Sim/PTH devices degraded in 16 days. Solution pH decreased from 7.4 to 6.96-
7.04 over the first 1-2 days and then was stable until the last time points, when 
the devices fully eroded. The ranges of pH for CB/Sim, CB/PTH, and Sim/PTH 
devices were 6.95-7.23, 6.97-7.37 and 6.96-7.28, respectively. Alternating 
release profiles were achieved by sequentially layering microspheres loaded with 
different biomolecules. 
 Figure 4.3 shows release profiles for devices designed to alternately 
release CB and PTH(1-34). Overall, five discrete release peaks were observed 
each for CB and PTH(1-34). To prevent early stage infection, CB release was 
maintained for three days at the beginning. During the release period, CB 
showed uniform peak concentrations (0.68-0.94 µg/ml), and PTH(1-34) also had 
relatively even maximum release (59-78 ng/ml), except for the last peak when 
integrity of the devices was lost. Figure 4.4 shows release characteristics of 
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devices alternately fabricated with CB and Sim. Again, prolonged CB release was 
observed over the first three days followed by five discrete release peaks for 
each component over a 15 day period.  The range of concentration of CB and 
Sim are 0.76-0.95 µg/ml and 1.26 -1.56 µM, 
respectively.
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Figure  4.2.  pH in sample solutions during degradation of 10-layer 
devices. Data are the mean of six replicates. Error bars, which ranged from 
11-28% of the mean, are not shown to prevent obscuring the curves. 
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 Figure 4.5 shows results for devices alternately loaded with Sim and 
PTH(1-34). Each release profile had 5 distinguishable peaks. In the Sim release 
profile, the first two peaks were sharp and high (1.58-1.65 µM), but the next two 
were relatively broad and gave lower concentrations (0.97-1.12 µM) than the first 
two. PTH(1-34) peaks showed relatively even release for the first four peaks 
(77.2-83.16 ng/ml), but a lower peak was observed for the late one (54.1 ng/ml). 
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Figure  4.3.  Release profile from 10-layered CB/PTH devices. Data are the 
mean of six replicates. Error bars, which ranged from 11-31% of the mean, 
are not shown to prevent obscuring the curves. 
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4.3.3  Effect of Combined Delivery of Biomolecules on Osteoblastic Cells 
In Figure 4.6 a, DNA contents in all MC3T3-E1 cultures increased until the 
seventh day and then showed relatively unchanging levels. Cells exposed to 1 
µg/ml CB with 10 nM Sim showed higher DNA content (5.64 µg/ml) than any 
other group (p<0.05). AP activity in all groups increased through the tenth day 
and then decreased, except for the 1 µM Sim group (Figure 4.6 b). As was 
observed for DNA content, the 10 nM Sim group had higher AP activity than any 
other group (p<0.05). Unlike DNA content, however, AP activity was higher for 
the 1 µM Sim group compared to controls (p<0.05).  
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Figure  4.4.  Release profile from 10-layered CB/Sim devices. Data are the 
mean of six replicates. Error bars, which ranged from 23-34% of the mean, 
are not shown to prevent obscuring the curves. 
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As shown in Figure 4.7 a, all CB and PTH(1-34) treatment groups had 
higher amounts of DNA (2.99-7.06 µg/ml) than did the control group (1.78- 3.37 
µg/ml) (p<0.05). Although not significantly different, cultures treated with 1 µg/ml 
CB and 5 ng/ml PTH(1-34) showed slightly higher DNA content until day 10. As 
seen for DNA contents, all CB and PTH(1-34) treatment groups had higher AP 
activity (Figure 4.7 b) (0.26-0.4  nM/min/µg/DNA) than did the control group 
(0.11-0.15 nM/min/µg/DNA)(p<0.05). All groups increased through the tenth day 
and then decreased slightly.  
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Figure  4.5.  Release profile from 10-layered Sim/PTH devices. Data are 
the mean of six replicates. Error bars, which ranged from 7-22% of the 
mean, are not shown to prevent obscuring the curves. 
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Figure  4.6  (a) DNA content and (b) AP activity in cultures exposed to 
alternating CB and Sim. 
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Figure  4.7.  (a) DNA content and (b) AP activity in cultures exposed to 
alternating CB and PTH. 
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In cultures exposed to alternating Sim and PTH(1-34), DNA contents 
mainly depended on Sim concentration (Figure 4.8 a). DNA contents for cells 
treated with 1 µM Sim were slightly higher than controls, whereas treatment with 
10 nM Sim resulted in 163-259% higher amounts of DNA than the controls 
(p<0.05). Furthermore, these two groups (10 nM Sim plus either 500 pg/ml or 5 
ng/ml PTH(1-34)) showed 39.8-101% and 14.6-40.3% higher DNA content than 
CB/Sim and CB/PTH groups, respectively (p<0.05). Alternating Sim and PTH 
cultures showed higher AP activity than did the control groups (Figure 4.8 b) 
(p<0.05). Furthermore, even 1 µM Sim treatment stimulated higher AP activity 
than in control groups throughout the two week experiments. 
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Figure  4.8.  (a) DNA content and (b) AP activity in cultures exposed to 
alternating Sim and PTH. 
 79
4.4  DISCUSSION 
The present study demonstrates alternating delivery of multiple 
biomolecules and shows that such alternating concentrations increase 
proliferation and early osteoblastic activity, which is critical to enhancing bone 
formation. The devices were based on reports of intermittent delivery of Sim and 
PTH(1-34) both promoting osteoblastic responses and bone formation 
[1,3,15,37,51,66,137]. The erodible polymeric devices, developed to allow 
intermittent release of a single molecule, alternating release of different 
molecules, or sequential release of multiple molecules, may offer a powerful 
approach in bone regeneration as well as in other medical therapies that involve 
multiple biological cascades.  
Drug loading and encapsulation efficiency are affected by volume of 
organic solvent used in dissolving the polymer [138,139] and the  initial drug 
concentration. The smaller volume of organic solvent in the system promotes 
precipitation of polymer. Drug loading increases with decreasing organic solvent 
volume and with increasing drug concentration. The size of CAP/PF-127 
microspheres used for the release devices can be controlled by modifying the 
emulsification process, such as by altering agitation velocity, time, temperature, 
and the parameters that influence the kinematic viscosity type, including 
concentration of polymer and emulsifier [140]. In our experiments, microsphere 
sizes ranged from 104 to 161 μm. It is thought that the differences of 
homogenization speed, water phase temperature, and types of drug are main 
reasons.   
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Blends of CAP, which is a well known enteric coating material in the 
pharmaceutical industry, and a nonionic surfactant, PF-127, which is used for 
stabilizing proteins and peptides, form an association polymer that undergoes 
surface erosion and shows zero-order release [16,46]. A number of ether sites in 
PF-127 and carboxylic acid groups in CAP form hydrogen bonds. When exposed 
to PBS, carboxyl groups on CAP become deprotonated, and hydrogen bonds 
with ether groups in PF-127 are consequently lost, resulting in surface erosion of 
the material.  
When CAP is dissolved in aqueous solution, deprotonation results in 
locally decreased pH. Measurement of pH showed only slight acidification below 
PBS’s initial pH of 7.4.  Supernatants remained close to neutral, with the lowest 
pH of just 6.95 occurring at the last time point sampled when the material was 
finally completely eroded. Disthabanchong et al. reported that a slightly acidic 
condition (pH 7.1) up-regulated PTH/PTHrP receptors and increased PTH 
binding to osteoblast-like cells compared to pH 7.4 [141]. In our experiments, the 
slight local acidification would not be expected to adversely affect differentiation 
of mesenchymal cells, which is reported to occur at pH [141] and may even up-
regulate expression of PTH receptors by cells. However, according to Brandao-
Burch’ group, at pH 6,9, acidosis reduced mineralization of bone nodules, 
osteoblast alkaline phosphatase activity was reduced, and downregulated 
messenger ribonucleic acid (mRNA) for alkaline phosphatase [142]. 
Two of the biomolecules used were incorporated because of their 
osteotropic effects.  Many in vitro and in vivo studies have been conducted to 
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explain the anabolic effect of intermittent infusion of PTH on bone formation. It is 
thought that PTH enhances proliferation of primary osteoblastic cells from 
humans and animals [10,65]. In addition, PTH exerts diverse effects on 
osteoblast differentiation depending on differentiation stage [13,67,68], and it 
stimulates alkaline phosphatase (AP) activity in the mouse osteoblastic cell line 
MC3T3-E1 [68]. Simvastatin promotes bone formation both in vitro and in vivo in 
animal models associated with increasing BMP-2 transcription [48,51,110].  
Devices used in this study were fabricated to fluctuate around daily 
between maximum and minimum release of drug and it was expected to be 
changed in a regular way.  Ideally, the minimum value of each profile would 
decrease to zero, because the adjacent layers do not contain the same 
biomolecules. However, low but measurable concentrations of drug were 
detected. It is thought that during fabrication of the multilayered devices, some 
microspheres in adjacent loaded and blank layers became intermingled under 
pressure, resulting in “contamination” of the drug-free layer. If absolutely zero 
concentration between peaks was needed, thicker blank layers could be made, 
although at the expense of increased overall thickness of the device.  In some 
release profiles, the last one or two peaks were lower than the first peaks 
because the drug could be diffused out before the device degraded through the 
PLGA coating. To maintain proper range of concentrations, drug loading of 
microspheres used for the last layers could be increased, if necessary, and more 
frequent sample collection-not once a day-would give more precise  information 
about release profiles.     
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All cultures treated with intermittent PTH showed increasing DNA content 
and AP activity. Unlike intermittent PTH delivery, exposure to 1 μM of simvastatin 
had an adverse effect on DNA content compared to other concentrations. This 
result corresponds to our previous findings [46]. Sim/PTH delivery devices 
showed higher DNA content and AP activity effect compared to CB/Sim, CB/PTH 
devices. This phenomenon results in an additive effect of Sim and PTH. The 
mechanism of Sim on bone formation is different from that of PTH. PTH 
stimulates multiple intracellular signal pathways, mediated by cAMP, and 
activates both protein kinase A (PKA) and C (PKC). However, the roles of each 
signal transduction system in osteoblast proliferation and differentiation are 
unknown [10]. Sim induces BMP-2 transcription through the inhibition of protein 
prenylation in osteoblasts and inhibits HMG-CoA reductase activity, resulting in 
the depletion of mevalonate in osteoblasts [51] 
One of the polymeric multiple biomolecules delivery systems used a 
scaffolds and drug loading methods into scaffolds is that one molecule is mixed 
in scaffold and another drug was encapsulated into microspheres. In this method 
Mooney’s group investigated dual growth factors delivery using PLGA scaffold for 
40 days. Another approach was made by Mikos’ group; they encapsulated dual 
growth factors and crosslinked them each other[94]. They seek for the target of 
traditional controlled release system-simultaneous sustained release system, 
whereas our devices were aimed at short term intermittent delivery.  
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4.5  CONCLUSION 
By alternatingly CAP and PF-127 microspheres loaded with CB and Sim, 
CB and PTH(1-34), or Sim and PTH(1-34), intermittent release with five 
distinguishable peaks for each of the two molecules were achieved. In vitro 
experiments showed that alternating delivery enhanced bioactivity of osteoblastic 
cells. Furthermore, alternating treatment with Sim and PTH(1-34) had an additive 
effect on cell responses. Overall, CAP/PF-127 polymer is a useful system for 
alternating, intermittent, or sequential delivery of multiple molecules, such as 
could be used for treatment of local bone defects. 
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CONCLUSION 
Using the association polymer system of CAP and PF-127, intermittent 
release profiles of Sim, PTH (1-34), Sim/CB, PTH/CB, and Sim/PTH were 
achieved. Release profiles can be controlled by altering CAP/PF-127 blending 
ratio, number of layers, and erosion conditions. From the results of these studies 
we find many evidences to support the hypothesis that cell responses to Sim and 
PTH containing devices depended on the mode of drug release. Sim treatments 
promoted osteoblastic activities and bone formation and PTH treatments 
enhanced osteoblastic activities compared to control cultures. Intermittently 
delivered Sim showed a greater anabolic effect in vitro and in vivo than sustained 
delivery. Combined devices with CB/Sim, CB/PTH and Sim/PTH showed five 
distinct peaks for each drug. All cultures treated with multiple molecules showed 
enhanced osteoblastic activity, and cultures with alternating Sim and PTH 
showed higher osteoblastic activities than Sim or PTH alone. It was clear that 
there was additive effect in Sim and PTH combined treatments. Consequently, 
these devices may lead to better treatments for local bone regeneration.   
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